Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study

The Lancet Oncology

Volumn 10, Issue 5, 2009, Pages 489-500

  Ciceri, Fabio ^a,b   Bonini, Chiara ^a,b   Stanghellini, Maria Teresa Lupo ^a,b   Bondanza, Attilio ^a   Traversari, Catia ^c   Salomoni, Monica ^c   Turchetto, Lucia ^c   Colombi, Scialini ^c   Bernardi, Massimo ^a   Peccatori, Jacopo ^a   Pescarollo, Alessandra ^a   Servida, Paolo ^a   Magnani, Zulma ^a   Perna, Serena K ^a,b   Valtolina, Veronica ^a   Crippa, Fulvio ^a   Callegaro, Luciano ^a   Spoldi, Elena ^c   Crocchiolo, Roberto ^a,b   Fleischhauer, Katharina ^a   Ponzoni, Maurilio ^a   Vago, Luca ^a   Rossini, Silvano ^a   Santoro, Armando ^d   Todisco, Elisabetta ^d   Apperley, Jane ^e   Olavarria, Eduardo ^e   Slavin, Shimon ^f   Weissinger, Eva M ^g   Ganser, Arnold ^g   Stadler, Michael ^g   Yannaki, Evangelia ^h   Fassas, Athanasios ^h   Anagnostopoulos, Achilles ^h   Bregni, Marco ^a,j   Stampino, Corrado Gallo ^c   Bruzzi, Paolo ⁱ   Bordignon, Claudio ^a,b,c   more..

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MOLMED S P A   (Italy)

^d Hematology   (Italy)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f BMT   (Israel)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h G PAPANICOLAOU HOSPITAL   (Greece)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j San Giuseppe Hospital   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THIOTEPA; THYMIDINE KINASE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GENE THERAPY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE CONTROL; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SUICIDE GENE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; FEMALE; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 65349157330     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70074-9     Document Type: Article

References (42)

1. Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 37 (2006) 439-449
2. Rocha V., Labopin M., Sanz G., et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351 (2004) 2276-2285
3. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998) 1186-1193
4. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
5. Ciceri F., Labopin M., Aversa F., et al. A survey of fully-haploidentical hematopoietic stem cells transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients transplanted in remission. Blood 112 (2008) 3574-3581
6. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004) 2265-2275
7. Gratwohl A., Baldomero H., Frauendorfer K., et al. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 39 (2007) 71-87
8. Dey B.R., and Spitzer T.R. Current status of haploidentical stem cell transplantation. Br J Haematol 135 (2006) 423-437
9. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 93 (1999) 467-480
10. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257 (1992) 238-241
11. Heslop H.E., Brenner M.K., Rooney C., et al. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 5 (1994) 381-397
12. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002) 3916-3922
13. Andre-Schmutz I., Le Deist F., Hacein-Bey-Abina S., et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 360 (2002) 130-137
14. Amrolia P.J., Muccioli-Casadei G., Huls H., et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108 (2006) 1797-1808
15. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
16. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 (2008) 1579-1586
17. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
18. Taylor P.A., Lees C.J., and Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99 (2002) 3493-3499
19. Gregori S., Bacchetta R., Hauben E., et al. Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Curr Opin Hematol 12 (2005) 451-456
20. Smith M., Barnett M., Bassan R., et al. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50 (2004) 197-222
21. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of MRD in adult ALL. Blood (2009) published online January 13. DOI:blood-2008-11-185132v1 (accessed March 25, 2009).
22. Sutherland D.R., Anderson L., Keeney M., et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5 (1996) 213-226
23. Mazzi B., Clerici T.D., Zanussi M., et al. Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. Leukemia 22 (2008) 2119-2122
24. Verzeletti S., Bonini C., Marktel S., et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 9 (1998) 2243-2251
25. Ciceri F., Bonini C., Marktel S., et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109 (2007) 4698-4707
26. Bondanza A., Valtolina V., Magnani Z., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 107 (2006) 1828-1836
27. Verfuerth S., Peggs K., Vyas P., et al. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood 95 (2000) 3990-3995
28. Sacre K., Carcelain G., Cassoux N., et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 201 (2005) 1999-2010
29. Marktel S., Magnani Z., Ciceri F., et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101 (2003) 1290-1298
30. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 18 (1974) 295-304
31. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
32. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
33. Alves N.L., Hooibrink B., Arosa F.A., et al. IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood 102 (2003) 2541-2546
34. Mehta J., Singhal S., Gee A.P., et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 33 (2004) 389-396
35. Bonini C., Bondanza A., Perna S.K., et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 15 (2007) 1248-1252
36. Gorin N.C., Labopin M., Boiron J.M., et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond-the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 24 (2006) 3959-3966
37. Bonini C., Ferrari G., Verzeletti S., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276 (1997) 1719-1724
38. Tiberghien P., Ferrand C., Lioure B., et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97 (2001) 63-72
39. Vago L., Forno B., Sormani M.P., et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 112 (2008) 3488-3499
40. Estey E.H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 14 (2000) 476-479
41. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117 (2007) 1466-1476
42. Kolb H.J., Schmid C., Barrett A.J., et al. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103 (2004) 767-776